搜索
Genmab A/S
GMAB添加自选
26.475USD
-0.615-2.27%
交易中 （美东）报价延迟15分钟
16.31B总市值
19.94市盈率 TTM
关于 Genmab A/S 公司
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Genmab A/S简介
公司代码GMAB
公司名称Genmab A/S
上市日期Oct 01, 2000
CEOVan De Winkel (Jan G.J)
员工数量2682
证券类型Depository Receipt
年结日Oct 01
公司地址Carl Jacobsens Vej 30
城市VALBY
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Denmark
邮编2500
电话4570202728
网址https://www.genmab.com/
公司代码GMAB
上市日期Oct 01, 2000
CEOVan De Winkel (Jan G.J)
Genmab A/S公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Mr. Rolf K. Hoffmann
Mr. Rolf K. Hoffmann
Independent Director
Independent Director
--
--
Ms. Deirdre P. Connelly
Ms. Deirdre P. Connelly
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Mr. Anthony Pagano
Mr. Anthony Pagano
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Ms. Martine J. Van Vugt, Ph.D.
Ms. Martine J. Van Vugt, Ph.D.
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
--
--
收入明细
单位: USD更新时间: 4月6日 周一
单位: USD更新时间: 4月6日 周一
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Royalties
3.10B
83.39%
Net product sales
398.00M
10.70%
Milestone payments
97.00M
2.61%
Collaboration revenue
70.00M
1.88%
Reimbursement income
53.00M
1.42%
地区USD
名称
营收
占比
Denmark
3.33B
89.41%
Japan
213.00M
5.73%
U.S.A
180.00M
4.84%
Netherlands
1.00M
0.03%
China
0.00
0.00%
业务
地区
业务USD
名称
营收
占比
Royalties
3.10B
83.39%
Net product sales
398.00M
10.70%
Milestone payments
97.00M
2.61%
Collaboration revenue
70.00M
1.88%
Reimbursement income
53.00M
1.42%
股东统计
更新时间: 2月19日 周四
更新时间: 2月19日 周四
持股股东
股东类型
持股股东
持股股东
占比
Orbis Investment Management Ltd.
2.35%
AllianceBernstein L.P.
1.77%
Paradigm BioCapital Advisors LP
1.15%
Arrowstreet Capital, Limited Partnership
0.81%
BlackRock Institutional Trust Company, N.A.
0.58%
其他
93.34%
持股股东
持股股东
占比
Orbis Investment Management Ltd.
2.35%
AllianceBernstein L.P.
1.77%
Paradigm BioCapital Advisors LP
1.15%
Arrowstreet Capital, Limited Partnership
0.81%
BlackRock Institutional Trust Company, N.A.
0.58%
其他
93.34%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
5.75%
Investment Advisor
3.72%
Hedge Fund
2.33%
Research Firm
0.24%
Bank and Trust
0.03%
Pension Fund
0.03%
Family Office
0.02%
其他
87.88%
机构持股
更新时间: 4月5日 周日
更新时间: 4月5日 周日
报告期
机构数
持股数
持股占比
持股变动
2026Q1
564
74.31M
12.10%
-2.99M
2025Q4
539
65.54M
10.64%
-9.83M
2025Q3
515
64.81M
10.54%
-15.68M
2025Q2
501
65.30M
10.31%
-6.21M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Orbis Investment Management Ltd.
14.42M
2.34%
+3.34M
+30.15%
Dec 31, 2025
AllianceBernstein L.P.
10.88M
1.77%
-76.82K
-0.70%
Dec 31, 2025
Paradigm BioCapital Advisors LP
7.04M
1.14%
+3.22M
+84.44%
Dec 31, 2025
Arrowstreet Capital, Limited Partnership
4.98M
0.81%
+1.33M
+36.64%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
3.58M
0.58%
+976.03K
+37.46%
Dec 31, 2025
Renaissance Technologies LLC
3.49M
0.57%
+671.31K
+23.79%
Dec 31, 2025
Harding Loevner LP
3.37M
0.55%
-114.34K
-3.28%
Dec 31, 2025
Parametric Portfolio Associates LLC
1.69M
0.27%
+109.58K
+6.93%
Dec 31, 2025
First Trust Advisors L.P.
1.34M
0.22%
-352.12K
-20.87%
Dec 31, 2025
Federated Hermes Global Investment Management Corp.
679.38K
0.11%
+256.44K
+60.63%
Dec 31, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Tema Oncology ETF
4.2%
First Trust NYSE Arca Biotechnology Index Fund
3.02%
WisdomTree BioRevolution Fund
1.31%
iShares Biotechnology ETF
1.15%
AB Disruptors ETF
0.69%
JPMorgan Healthcare Leaders ETF
0.28%
First Trust NASDAQ BuyWrite Income ETF
0.26%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
ActivePassive International Equity ETF
0.12%
查看更多
Tema Oncology ETF
占比4.2%
First Trust NYSE Arca Biotechnology Index Fund
占比3.02%
WisdomTree BioRevolution Fund
占比1.31%
iShares Biotechnology ETF
占比1.15%
AB Disruptors ETF
占比0.69%
JPMorgan Healthcare Leaders ETF
占比0.28%
First Trust NASDAQ BuyWrite Income ETF
占比0.26%
ProShares Ultra Nasdaq Biotechnology
占比0.12%
Invesco Nasdaq Biotechnology ETF
占比0.12%
ActivePassive International Equity ETF
占比0.12%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
